BlackRock’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-127,723
Closed -$50.8K 5562
2023
Q3
$50.8K Sell
127,723
-2,153
-2% -$1.06K ﹤0.01% 4999
2023
Q2
$89.6K Buy
129,876
+33,527
+35% +$216K ﹤0.01% 4947
2023
Q1
$760K Sell
96,349
-4,276
-4% -$14.9K ﹤0.01% 4416
2022
Q4
$90.6K Hold
100,625
﹤0.01% 5071
2022
Q3
$110K Hold
100,625
﹤0.01% 5152
2022
Q2
$124K Sell
100,625
-20,064
-17% -$26.8K ﹤0.01% 5175
2022
Q1
$285K Sell
120,689
-981
-0.8% -$2.33K ﹤0.01% 5026
2021
Q4
$378K Buy
121,670
+1,050
+0.9% +$3.49K ﹤0.01% 4955
2021
Q3
$490K Buy
120,620
+4,138
+4% +$17.2K ﹤0.01% 4757
2021
Q2
$564K Sell
116,482
-205,300
-64% -$921K ﹤0.01% 4665
2021
Q1
$1.67M Buy
321,782
+7,165
+2% +$49.9K ﹤0.01% 4346
2020
Q4
$2.1M Buy
314,617
+28,160
+10% +$231K ﹤0.01% 4028
2020
Q3
$2.92M Buy
286,457
+1,006
+0.4% +$11.8K ﹤0.01% 3792
2020
Q2
$3.58M Buy
+285,451
New +$3.99M ﹤0.01% 3650
2019
Q3
Sell
-1,158
Closed -$11K 5130
2019
Q2
$11K Sell
1,158
-2,932
-72% -$28.1K ﹤0.01% 4764
2019
Q1
$40K Sell
4,090
-281
-6% -$3.1K ﹤0.01% 4508
2018
Q4
$52K Sell
4,371
-80
-2% -$1.16K ﹤0.01% 4470
2018
Q3
$72K Buy
4,451
+181
+4% +$4.3K ﹤0.01% 4504
2018
Q2
$155K Sell
4,270
-893
-17% -$30.9K ﹤0.01% 4373
2018
Q1
$161K Buy
5,163
+795
+18% +$25.3K ﹤0.01% 4253
2017
Q4
$169K Buy
4,368
+299
+7% +$7.84K ﹤0.01% 4245
2017
Q3
$87K Buy
4,069
+890
+28% +$16.5K ﹤0.01% 4387
2017
Q2
$63K Buy
+3,179
New +$65.8K ﹤0.01% 4485

Other funds holding BLPH

BlackRock's BLPH Position: Q4 2023 in Review

BlackRock sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q4 2023, closing a stake of 127,723 shares — an estimated $50.8K sold.

BlackRock first reported a position in BLPH in Q2 2017 and held it in 23 quarters. The position peaked at $3.58M in Q2 2020. 2 funds tracked by Wall St. Rank hold BLPH as of Q4 2023.

  • BlackRock reported no remaining Bellerophon Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
  • BlackRock sold 127,723 Bellerophon Therapeutics, Inc. shares in Q4 2023, an estimated $50.8K.
  • BlackRock first reported a position in Bellerophon Therapeutics, Inc. in Q2 2017 and held it in 23 quarters.
  • BlackRock's Bellerophon Therapeutics, Inc. position peaked at $3.58M in Q2 2020.
  • 2 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q4 2023.

Based on BlackRock's 13F filing for Q4 2023, filed 13 Feb 2024.